Clinical data in relation to DOCK8 status are shown in Supplementary Table S3, and change in eczema treatment parameters (estimated marginal means) during the study in patients with and without possibly pathogenic DOCK8 variants is shown in Figure 3a−d. This evidence concerns the gene DOCK8 and Eczematoid dermatitis.